Adynxx, Inc.
ADYX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$581
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $581.00 |
|---|---|
| Enterprise Value | $9.15 Million |
| Earnings per Share | $-10.26 |
| Beta | -8.54 |
| Outstanding Shares | 5,807,877 |
Return
| Return on Equity | 78.89% |
|---|---|
| Return on Assets | -268.19% |
| Return on Invested Capital | 60.69% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 15.54 |
| Enterprise Value to EBIT | -1.43 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.04 |
| Debt to Equity | -0.86 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Adynxx, Inc.
6 employees
CEO: Richard Orr
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of tra...